---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-025762"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:56:37.551573+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Windtree terminates SEISMiC-C study of istaroxime after 20 enrollments; cites limited resources

## Summary
- Terminated Phase 2 SEISMiC-C trial (istaxime for cardiogenic SCAI Stage C) at 20 enrollments.
- Decision driven by limited resources and desire to advance istaroxime into broader acute heart failure.
- No safety concerns were cited as the reason for termination.
- CEO Jed Latkin confirmed the termination in the 8-K filing filed August 8, 2025.

## SEC filing metadata
- accession: 0001437749-25-025762
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774925025762/0001437749-25-025762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774925025762/wint20250808_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-025762
- JSON: https://secwatch.observer/filing/0001437749-25-025762.json
- Plain text: https://secwatch.observer/filing/0001437749-25-025762.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.